Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    20-May-2000      
Issue 37 Next Update - 14:00 UTC 08:00 EST    21-May-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya




















Back To Vidyya FDA Approves New Cancer Drug


Orphan Drug For Treatment Of CD33 Positive Acute Myeloid Leukemia

FDA approved a new drug, Mylotarg, for the treatment of CD33 positive acute myeloid leukemia. The drug is approved for patients 60 years or older who have relapsed for the first time and are poor candidates for cytotoxic therapy. Mylotarg was approved as an orphan drug, a drug intended for the treatment of rare diseases or conditions.

This new treatment is given in IV form as a 2-hour infusion in two doses given fourteen days apart. Standard chemotherapy is given in the hospital for 7 days and requires patients to be hospitalized for an extended period of time.

Myeloid leukemia is characterized by a rapid accumulation of abnormal white blood cells in the blood and bone marrow, resulting in severe anemia, infection, and hemorrhage during the course of the disease.

Three clinical studies with Mylotarg involved 142 patients with surrogate markers based on rates of complete remission. A total of 80 patients were age 60 or older. Side effects included liver toxicity. During the clinical trials 14 to 24 percent of patients showed elevations in liver enzymes leading to clinical liver disease and jaundice.

Mylotarg (Gemtuzumab Ozogomicin for injection) is manufactured by Wyeth Ayerst of Philadelphia, Pa. The company's Web site can be reached at http://www.ahp.com/wyeth.htm.



Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.